 |
More: HIV Management 2008: The New York Course NY Course 2008: HIV Resistance Issues CME April 24 - 25, 2008, New York, NY Author Information and Disclosures This activity was developed in collaboration with HIV Management 2008: The New York Course.
HIV Management 2008: The New York Course is an online educational collaboration between Albert Einstein College of Medicine and Medscape
Release Date: May 30, 2008; Valid for credit through May 30, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and were developed in collaboration with the HIV Management 2008: The New York Course. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Better understand viral and host factors that govern the emergence of HIV drug resistance
- Distinguish between acquired and transmitted drug resistance, the significance for public health, and the requirement for a resistance
genotype
- Understand the concept of a "genetic barrier for drug resistance"
- Characterize the resistance patterns of newer agents
- Consider the implications of these resistance patterns for clinical management strategies
Authors and Disclosures Mark A. Wainberg, PhD
Disclosure: Mark A. Wainberg, PhD, has disclosed that he has received grants and/or research support from GlaxoSmithKline, Gilead, Merck, and Pfizer. Dr. Wainberg has also disclosed that he has served as a consultant to GlaxoSmithKline, Merck, and Pfizer, and that he has served on the speaker's bureau for GlaxoSmithKline, Gilead, Abbott, and Pfizer. Daniel R. Kuritzkes, MD
Disclosure: Daniel R. Kuritzkes, MD,
has disclosed that he has served as a consultant to Abbott, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Human Genome Sciences, Merck, Monogram Biosciences, Panacos, Pfizer, Roche, Schering-Plough, Siemens, Tibotec, Johnson & Johnson, Trimeris, and VIRxSYS. Dr. Kuritzkes has also disclosed that he has received honoraria from Abbott, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Human Genome Sciences, Merck, Monogram
Biosciences, Panacos, Pfizer, Roche, Schering-Plough, Siemens, and VIRxSYS, and that he has received grant support from Boehringer Ingelheim, Gilead, Human Genome Sciences, Merck, Roche, Schering-Plough, and Trimeris. |
 |
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. All other healthcare professionals completing continuing education credit for this activity will be issued a certificate of participation.
Albert Einstein College of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
